Shots:
BMS has reported topline data from P-III (EXCALIBER-RRMM) trial, assessing Zenbexus+ daratumumab & dexamethasone (ZDd; n=400) vs daratumumab + bortezomib + dexamethasone (DVd; n=400) in 800 pts with MM, as early as first relapse
At an mFU of 23mos., trial showed improvement in the dual-1EP of PFS, with mPFS of 42 vs 20mos., demonstrating…
